N-Arylsulfonyl-3-aminoalkoxyindoles Field of Invention: The present invention includes compounds described by general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any suitable combination of the above. Further the present invention also includes the processes for preparing such compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bioactive metabolites and also includes any suitable combination of the above. The invention also describes various methods of administering these compounds of general formula (I), i.e. pharmaceutically acceptable dosage forms compositions and the use of such compounds and compositions in either therapy or diagnosis. The compounds of the general formula (I) of this invention are 5-HT (Serotonin) ligands e.g. agonists or antagonists. The compounds of the general formula (I) of this invention, by the virtue of Its chemical characteristic, could either Independently or simultaneously modulate the melatonln receptor I.e. either these compounds are melatonergic ligands e.g. agonists or antagonists, or they Interact with both 5-HT and/or Melatonin receptors. Thus, compounds of general formula (I) of this invention are useful for treating diseases wherein activity of either 5-HT (Serotonin) and/or Melatonin is modulated to obtain the desired therapeutic effect. Specifically, the compounds of this invention are useful in the treatment and / or prophylaxis of conditions such as psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, anxiety, migraine headache, depression, drug addiction, convulsive disorders, personality disorders, hype/tension, autism, post-traumatic stress syndrome, alcoholism, panic attacks, obsessive-compulsive disorders, chronobiological abnormalities, circadian rhythms, anxiolytic, osteoporosis, ischemic stroke, lower the risk of SIDS in young infants with low endogenous melatonin levels, reproduction, glaucoma and sleep disorders. Hence, the compounds, of general formula (I) of this invention could also be useful in treating the psychotic, affective, vegetative and psychomotor symptoms of schizophrenia and the extrapyramidal motor side effects of other antipsychotic drugs; neurodegenerative disorders like Alzheimer's disease, Parkinson's and Huntington's chorea and chemotherapy-induced vomiting; and in modulation of eating behavior and thus are useful in reducing the morbidity and mortality associated with excess weight. Background of the Invention Many diseases of the central nervous system are influenced by the adrenergic, the dopaminergic and the serotoninergic neurotransmitter systems. Serotonin has been implicated in numerous diseases and conditions, which originate from central nervous system. The list includes diseases and conditions related to sleeping, eating, perceiving pain, controlling body temperature, controlling blood pressure, depression, anxiety, schizophrenia and other bodily states. (References: Fuller, R. W., Drugs Acting on Serotoninergic Neuronal Systems, in "Biology of Serotoninergic Transmission", ed. by Osborne N. N., J Wiley & Sons Inc. (1982), 221-247; Boullin D. J., et. al., in "Serotonin in Mental Abnormalities", International Association for The Scientific Study of Mental Deficiency, Wiley, Checester, 1978, pp. 1-340; Barchas J. et. al., in "Serotonin and Behavior", Academic Press, NY (1973)). Serotonin also plays an important role in the peripheral systems, such as the gastrointestinal system, where it has been found to mediate a variety of contractile, secretory and electrophysiologic effects. Due to the broad distribution of serotonin within the body, there is a lot of interest and use, in the drugs that affect serotoninergic systems. Particularly, preferred are the compouiids which have receptor-specific agonism and/or antagonism for the treatment of a wide range of disorders, including anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, certain other neurodegenerative disorders like Alzheimer, Parkinson, Huntington's chorea and chemotherapy-induced vomiting (References: Gershon M. D. et. al., 5-Hydroxytryptamine and enteric neurons. In: The Peripheral Actions of 5-Hydroxytryptamine, edited by J. R. Fozard. New York: Oxford, 1989, p. 247-273; Saxena P. R., et al., Journal of Cardiovascular Pharmacology (1990), supplement 15, p. 17-34). The major classes of serotonin receptors (5-HT1-7) contain fourteen to eighteen separate receptors that have been formally classified (References: Glennon et al, Neuroscience and Behavioral Reviews (1990), 14, 35; and Hoyer D. et al, Pharmacol. Rev. (1994), 46, 157-203). Recently discovered information regarding sub-type identity, distribution, structure and function suggests that it is possible to identify novel, sub-type specific agents having improved therapeutic profiles with lesser side effects. The 5-HT6 receptor was identified in 1993 (References: Monsma et al, Mol. Pharmacol. (1993), 43, 320-327; and Ruat M. et al, Biochem. Biophys. Res. Com. (1993), 193, 269-276). Several antidepressants and atypical antipsychotics bind to the 5-HT6 receptor with high affinity and this binding may be a factor in their profile of activities (References: Roth et al, J. Pharm. Exp. Therapeut. (1994), 268, 1403-1410; Sleight et al, Exp. Opin. Ther. Patents (1998), 8, 1217-1224; Bourson et al, Brit. J. Pharmacol. (1998), 125, 1562-1566; Boess et al, Mol. Pharmacol., 1998, 54, 577-583; Sleight et al, Brit. J. Pharmacol. (1998), 124, 556-562). In addition, 5-HT6 receptor has been linked to generalized stress and anxiety states (Reference: Yoshioka et al, Life Sciences (1998), 17/18, 1473-1477). Together these studies and observations suggest that the compound, which antagonizes 5-HT6 receptors, will be useful in treating various disorders of the central nervous system. There is very strong evidence that Melatonin is important for the regulation of a variety of neural and endocrine functions, especially those that exhibit circadian and circannual rhythmlcity. Great Interest therefore lies in the possibility of making available to the clinician melatonin analogues that are metabolically more stable and have an agonist or antagonist character and of which the therapeutic effect may be expected to be superior to that of the hormone itself. PCT patent application WO 00/72815 and U.S. patent No 6,465,66081 gives extensive literature on studies with Melatonin and potential therapeutic application of various llgands reported till date. Those various effects are exerted via the intermediary of specific Melatonin receptors. Molecular biology studies have demonstrated the txlstenct of a number of receptor sub-types that are capable of binding that hormone (Trends Pharmacol. Sci., 1995, 16, p. 50; WO 97 04094). Melatonin acts on the CNS to affect neural mechanisms through receptors located in the brain. Additionally, a number of studies indicate the existence of direct effects of Melatonin in peripheral organs via peripheral melatonin receptors. Melatonin receptors are present in the heart, lungs, prostate gland, gonads, white blood cells, retina, pituitary, thyroid, kidney, gut and blood vessels (Withyachumnarnkul et al., Life Sci, 12 65, 1986). Three Melatonin receptor subtypes have been identified so far MT-I , MT-2 and Mel 1 c (Barreft et al., Biol. Signals Recept., 1999, 8: 6-14). There is evidence suggesting both Melatonin agonists and antagonists would be of potential therapeutic use for a variety of maladies and conditions. PCT application WO 00/72815 and U.S patent No. 6,465,660B1 discuss in depth applications and use of such compounds and details of which are incorporated herein by reference. Also U.S. patent 6,465,660 and U.S. patent application publication number U.S. 2003/0105087 discuss some tricyclic indole and tricyclic azaindole derivatives having very valuable pharmacological characteristics in respect of melatoninergic receptors. U.S. Patent. No. 4,839,377 and U.S. Patent. No. 4,855,314 refers to 5-substituted 3-aminoalkyl indoles. The compounds are said to be useful for the treatment of migraine. British Patent 2,035,310 refers to 3-aminoalkyl-1H-indole-5-thioamides and carboxamides. The compounds are said to be useful in treating hypertension, Raymond's disease and migraine. European Patent Publication 303,506 refers to 3-polyhydropyridyl-5-substituted-1H-indoles. The compounds are said to have 5-HTi receptor agonists and vasoconstrictor activity and to be useful in treating migraine. European Patent Publication 354,777 refers to N-piperidinylindolylethyl-alkane sulfonamide derivatives. The compounds are said to be 5-HT1 receptor agonists and have vasoconstrictor activity and are useful in treating cephalic pain. European Patent Publication 438,230, refers to indole-substituted five-membered heteroaromatic compounds. The compounds are said to have "5-HTrlike" receptor agonist activity and to be useful in the treatment of migraine and other disorders for which a selective agonist of these receptors is indicated. European Patent Publication 313,397 refers to 5-heterocyclic indole derivatives. The compounds are said to have exceptional properties for the treatment and prophylaxis of migraine, cluster headache and headache associated with vascular disorders. These compounds are also said to have exceptional "5-HT-like" receptor agonism. International Patent Publication WO 91/18897 refers to 5-heterocyclic indole derivatives. The compounds are said to have exceptional properties for the treatment and prophylaxis of migraine, cluster headache, and headache associated with vascular disorders. These compounds are also said to have exceptional "5-HT-like" receptor agonism. European Patent Publication 457,701 refers to aryloxy amine derivatives as having high affinity for 5-HT1D serotonin receptors. These compounds are said to be useful for treating diseases related to serotonin receptor dysfunction, for example, migraine. European Patent Publication 497,512 A2, refers to a class of imidazole, triazole and tetrazole derivatives that are selective agonists for "5-HT-like" receptors. These compounds are said to be useful for treating migraine and associated disorders. International Patent Publication WO 93/00086 describes a series of tetrahydrocarbazole derivatives, as 5-HT1 receptor agonists, useful for the treatment of migraine and related conditions. International Patent Publication WO 93/23396, refers to fused imidazole and triazole derivatives as 5-HTi receptor agonists, for the treatment of migraine and other disorders. Schoeffter P. et al. refers to methyl 4-{4-[4-(1,1,3-trioxo-2H-1,2-benzoisothiazol-2-yl)butyl]-1-piperazinyl}1H-indole-3-carboxylate as a selective antagonist for the 5-HT1A receptor in their paper "SDZ216-525, a selective and potent 5-HT1A receptor antagonist", European Journal of Pharmacology, 244, 251-257 (1993). International Patent Publication WO 94/06769, refers to 2-substituted-4-piperazine-benzothlophene derivatives that are serotonin 5-HTu and 5-HT1D receptor agents useful in the treatment of anxiety, depression, migraine, stroke, angina and hypertension. Summary of the Invention: The present invention relates to compounds of general formula (I), its stereoisomers, Its radioisotopes, its geometric forms, its N-oxide, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any suitable combination of the above. The compounds of general formula (I) are as follows, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, heterocyclylalkoxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl arylalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazino, hydroxylamino, carboxylic acid and its derivatives, sulfonic acids and its derivatives, phosphoric acid and its derivatives; or the adjacent groups like R1 and R2 or R2 and R3 or R3 and R4 or R5 and R6 or R6 and R7 or R7 and R8 or R8 and R9 together with carbon atoms to which they are attached may form a five or a six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from 0, N, S and combinations of double bond and heteroatoms; or R11 and R12 together with carbon atoms to which they are attached may form a three to a six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from 0, N, S and combinations of double bond and heteroatoms. Rio represents hydrogen, halogen, perhaloalkyl, substituted or unsubstituted groups selected from linear or branched (Ci-C3)alkyl and aryl. R13 and R14 represents hydrogen, alkyl, aryl, aralkyl or together with nitrogen atom form a cyclic three to seven membered ring, optionally, R11 and R13 together may form a part of cyclic structure along with the intervening nitrogen and carbon atoms; the heterocycle may have either one, two or three double bonds; optionally it may also contain one to three heteroatom selected from the group of oxygen, nitrogen and sulfur, and includes ring fused with any carbocyclic or heterocyclic ring, which can be saturated or unsaturated. V is an integer ranging from 1 to 8, preferably 1 to 4, wherein the carbon chains which "n" represents may be either linear or branched. "m" is an integer ranging from 0 to 2 preferably m is 1 or 2; along with the proviso that whenever m = 2 and each of R5, R6, R7, R8 and R9 are hydrogens then all of R1f R2) R3, R4 and R10, together are never hydrogens. or a stereoisomer, or a polymorph, or any suitable combination of above such as a nitrogen oxide thereof; a prodrug of the compound or the nitrogen oxide; a pharmaceutically acceptable salt of the compound, the nitrogen oxide, or the prodrug; or a solvate or hydrate of the compound, the nitrogen oxide, the prodrug or the pharmaceutically acceptable salt. The present invention also relates to the process for preparing the compound of the general formula (I) Its stereolsomere, its radlolsotopes, its geometric forms, its N-oxide, its polymorphs, Its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bioactive metabolites and any suitable combination of above. In the case of the compounds of general formula (I), where tautomerism may exist, the present invention relates to all of the possible tautomeric forms and the possible mixture thereof. The present invention also relates to the stereoisomers, which as a rule are obtained as racemates that can be separated into the optically active isomers in a manner known per se. The present invention also relates to radio-labeled isotopes, which are identical to those defined in the general formula (I), but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number found usually in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, iodine, bromine and mecnitium, exemplified by 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 18F, 99mTc, 31P, S, 123I and 125I. Those compounds of general formula (I) as described earlier containing the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. In the case of the compounds of general formula (I) containing geometric isomerism the present invention relates to all of these geometric isomers. The term "nitrogen oxide" or "N-oxide" refers to the oxidation of at least one of the two nitrogens in the compounds of general formula (I) (e.g., mono- or di-oxide). The nitrogen mono-oxides may exist as a single positional isomer or a mixture of 2° positional isomers (e.g., a mixture of 1-N-oxide and 4-N-oxide piperazine or a mixture of 1-N-oxide and 4-N-oxide plperazines). Suitable pharmaceutically acceptable acid addition salts of compounds of the general formula (I) can be prepared of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, includes, salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, 9ulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benezenesulfonate, p-toiunesulfonate, palmeate and oxalate. Pharmacsutically acceptable salts forming part of this invention are intended to define but not limited to the above list. Suitable pharmaceutically acceptable base addition salts of compounds of the general formula (I) can be prepared of the aforementioned acid compounds of this invention are those which form non-toxic base addition salts, includes, salts containing pharmaceutically acceptable cations, such as Lithium, sodium, potassium, calcium and magnesium, salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline, tromethamine and the like; ammonium or substituted ammonium salts. Pharmaceutically acceptable salts forming part of this invention are intended to define but not limited to the above list. In addition, pharmaceutically acceptable salts of the compound of formula (I) can be obtained by converting derivatives which have tertiary amino groups into the corresponding quarternary ammonium salts in the methods known in the literature by using quarternizing agents. Possible quartemizing agents are, for example, alkyl halides such as methyl iodide, ethyl bromide and n-propyl chloride, including arylalkyl halides such as benzyl chloride or 2-phenylethyl bromide. In the addition to pharmaceutically acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of the compounds, in the preparation of other salts, or in the identification and characterization of the compounds or intermediates. The pharmaceutically acceptable salts of compounds of formula (I) may exists as solvates, such as with water, methanol, ethanol, dimethylformamide, ethyl acetate, and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent, of crystallization, inherent in the solvent preparation or crystallization, or adventitious to such solvent. Such solvates are within the scope of this invention. The invention also encompasses the pharmaceutically acceptable prodrugs of the compound! of tht formula (I), A prodrug is a drug which has been chemically modified and may be biologically in-active at the site of action, but which may be degraded or modified by one or more enzymatic or other in-vivo processes to the parent form. This prodrug should have a different pharmacokinetic profile than the parent, enabling easier absorption across the mucosal epithelium, better salt formation, or solubility, and/or Improved systemic stability (an increase in the plasma half-life, for example), Typically, such chemical modifications include the following: 1. ester or amide derivatives which may be cleaved by esterases or lipases; 2. peptides which may be recognized by specific or non-specific proteases; or 3. derivatives that accumulate at a site of action through membrane selection of a prodrug from or a modified prodrug form; or 4. any combination of 1 to 3, above. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in H. Bundgard, Design of prodrugs, (1985). Another aspect of the present invention comprises of a pharmaceutical composition, containing at least one of the compounds of the general formula (I), their derivatives, their analogs, their derivatives, their stereoisomers, their polymorphs, their pharmaceuticaily acceptable salts, their pharmaceutically acceptable solvates thereof as an active ingredient, together with pharmaceutically employed carriers, auxiliaries and the like. An effective amount of a compound of general formula (I) or its salt is used for producing medicaments of the present invention, along with conventional pharmaceutical auxiliaries, careers and additives. The present invention also relates to the pharmaceutically acceptable compositions containing them, and the use of these compounds and compositions in medicine. The compounds of general formula (I) of this invention are useful in the treatment and/ or prophylaxis of a condition wherein modulation of 5-HT activity is desired. The compounds of general formula (I) of this invention are useful in the treatment and/ or prophylaxis of a condition wherein modulation of melatonin activity is desired. The compounds of general formula (I) of this invention are useful in the treatment and/ or prophylaxis of a condition wherein modulation of 5-HT and melatonin activities gives desired effect. The present invention provides for use of the compounds of general formula (I) according to above, for the manufacture of the medicaments for the potential use in the treatment and/ or prophylaxis of certain CNS disorders such as, anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders e.g. Alzheimer's disease and age-related cognitive decline, ADHD (Attention Deficient Disorder/ Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schlzophreniform disorders, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, panic attacks, chronobiological abnormalities, clrcadlen rhythms, anxiolytic, osteoporosis, ischemic stroke, lower the risk of SIDS In young Infants with low endogenous melatonin levels, reproduction, glaucoma, sleep disorders (including disturbances of Orcadian rhythm) and also disorders associated with spinal trauma and / or head injury such as hydrocephalus. Compounds of the invention are further expected to be of use in the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and Huntington's chorea. The compounds of the invention are also expected to be of use in the treatment of certain Gl (Gastrointestinal) disorders such as IBS (Irritable bowel syndrome) or chemotherapy induced emesis. The compounds of the invention are also expected to be of use in the modulation of eating behavior and these compounds can also be used to reduce morbidity and mortality associated with the excess weight. The present invention provides a method for the treatment of a human or a animal subject suffering from certain CNS disorders such as, anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders e.g. Alzheimer's disease and age-related cognitive decline, ADHD (Attention Deficient Hyperactivity Disorder), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, panic attacks, chronobiological abnormalities, circadian rhythms, anxiolytic, osteoporosis, ischemic stroke, lower the risk of SIDS in young infants with low endogenous melatonin levels, reproduction, glaucoma, sleep disorders (including disturbances of Circadian rhythm) and also disorders associated with spinal trauma and /or head injury such as hydrocephalus. Compounds of the invention are further expected to be of use in the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and Huntington's chorea. The present invention also provides a method for modulating 5-HT and/ or melatonin receptor function desired in certain cases. Compounds of the present invention may be administered in combination with other pharmaceutical agents, such as apo-B/MTP inhibitors, MCR-4 agonists, CCK-A agonists, monoamine reupta